These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19182214)

  • 1. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study.
    Rogowski WH
    Med Decis Making; 2009; 29(2):224-38. PubMed ID: 19182214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping.
    Adams PC; Valberg LS
    Am J Gastroenterol; 1999 Jun; 94(6):1593-600. PubMed ID: 10364030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching for hereditary hemochromatosis.
    Laudicina RJ
    Clin Lab Sci; 2006; 19(3):174-83. PubMed ID: 16910235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening for hereditary hemochromatosis.
    Phatak PD; Guzman G; Woll JE; Robeson A; Phelps CE
    Arch Intern Med; 1994 Apr; 154(7):769-76. PubMed ID: 8147681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms.
    Gagné G; Reinharz D; Laflamme N; Adams PC; Rousseau F
    Clin Genet; 2007 Jan; 71(1):46-58. PubMed ID: 17204047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
    Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
    Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Using value of information analysis in decision making about applied research. The case of genetic screening for hemochromatosis in Germany].
    Rogowski WH; Grosse SD; Meyer E; John J; Palmer S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 May; 55(5):700-9. PubMed ID: 22526859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia].
    Oliva J; López-Bastida J; Moreno SG; Mata P; Alonso R
    Rev Esp Cardiol; 2009 Jan; 62(1):57-65. PubMed ID: 19150015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic screening for iron overload: No evidence of discrimination at 1 year.
    Hall MA; Barton JC; Adams PC; McLaren CE; Reiss JA; Castro O; Ruggiero A; Acton RT; Power TE; Bent TC
    J Fam Pract; 2007 Oct; 56(10):829-34. PubMed ID: 17908514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness.
    Adams PC; Kertesz AE; Valberg LS
    Hepatology; 1995 Dec; 22(6):1720-7. PubMed ID: 7489980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older.
    Baer DM; Simons JL; Staples RL; Rumore GJ; Morton CJ
    Am J Med; 1995 May; 98(5):464-8. PubMed ID: 7733125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
    Smith KJ; Monsef BS; Ragni MV
    Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.
    Ingles J; McGaughran J; Scuffham PA; Atherton J; Semsarian C
    Heart; 2012 Apr; 98(8):625-30. PubMed ID: 22128210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins.
    Stollenwerk B; Gerber A; Lauterbach KW; Siebert U
    Med Decis Making; 2009; 29(5):619-33. PubMed ID: 19773581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for hemochromatosis: phenotype versus genotype.
    Edwards CQ; Griffen LM; Ajioka RS; Kushner JP
    Semin Hematol; 1998 Jan; 35(1):72-6. PubMed ID: 9460810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Should we support large-scale screening for genetic haemochromatosis in France?].
    Deugnier Y; Le Gall JY
    Bull Acad Natl Med; 2004; 188(2):265-72; discussion 272-3. PubMed ID: 15506717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis.
    Patch C; Roderick P; Rosenberg W
    J Hepatol; 2005 Jul; 43(1):149-55. PubMed ID: 15876471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis.
    Nisselle AE; Delatycki MB; Collins V; Metcalfe S; Aitken MA; du Sart D; Halliday J; Macciocca I; Wakefield A; Hill V; Gason A; Warner B; Calabro V; Williamson R; Allen KJ
    Clin Genet; 2004 May; 65(5):358-67. PubMed ID: 15099342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hemochromatosis in the Puerto Rico veteran population.
    Pérez R; Toro D; Fournier J; Villanueva A
    P R Health Sci J; 2007 Jun; 26(2):147-50. PubMed ID: 17722428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.